LAVA Therapeutics N.V.
LVTX
$1.28
$0.043.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 37.92% | -39.15% | 34.68% | 96.03% | 57.12% |
| Total Depreciation and Amortization | 29.94% | -33.33% | -22.71% | -21.09% | -215.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -149.56% | 1,249.20% | -120.36% | -111.30% | -53.73% |
| Change in Net Operating Assets | 153.42% | -18.40% | 91.47% | -118.24% | -115.44% |
| Cash from Operations | 88.07% | -21.43% | 35.83% | 86.50% | -132.95% |
| Capital Expenditure | 100.00% | -283.33% | -- | -- | 99.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 226.36% | 102.78% | -25.00% | -92.31% | -124.24% |
| Cash from Investing | 226.28% | 102.65% | 51.34% | -90.65% | -109.91% |
| Total Debt Issued | -- | -10.21% | 9.32% | 11.11% | -- |
| Total Debt Repaid | -127.99% | 55.06% | 48.73% | 35.51% | 723.73% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -127.99% | 23.65% | 103.18% | 100.00% | 4,700.00% |
| Foreign Exchange rate Adjustments | -200.93% | 184.58% | -6,200.00% | -162.09% | -70.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 143.68% | 67.44% | 37.67% | -485.24% | -151.20% |